Johnson & Johnson (J&J) is being investigated by the US Federal Trade Commission (FTC) over concerns that the contracting practices for its arthritis drug, Remicade, violated antitrust laws. The FTC has accused J&J of using a “sweetheart deal” to win contracts with Medicare and Medicaid in exchange for lowering prices on other drugs. Lucas Jackson The investigation follows a lawsuit filed in 2017 by Pfizer, which claimed that J&J's contracts with health insurers for Remicade were anticompetitive and designed to block sales of Pfizer's rival product, Inflectra.
Johnson & Johnson (J&J) is being investigated by the US Federal Trade Commission (FTC) over concerns that the contracting practices for its arthritis drug, Remicade, violated antitrust laws. The FTC has accused J&J of using a “sweetheart deal” to win contracts with Medicare and Medicaid in exchange for lowering prices on other drugs. The investigation follows a lawsuit filed in 2017 by Pfizer, which claimed that J&J's contracts with health insurers for Remicade were anticompetitive and designed to block sales of Pfizer's rival product, Inflectra.